Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method

[1]  K. Blennow,et al.  Identification of novel N-terminal fragments of amyloid precursor protein in cerebrospinal fluid , 2010, Experimental Neurology.

[2]  M. Weiner,et al.  Cerebrospinal fluid and plasma biomarkers in Alzheimer disease , 2010, Nature Reviews Neurology.

[3]  Aneeka M Hancock,et al.  DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.

[4]  Thomas Foltynie,et al.  The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. , 2009, Brain : a journal of neurology.

[5]  David R. Williams,et al.  Biological fluid biomarkers in neurodegenerative parkinsonism , 2009, Nature Reviews Neurology.

[6]  W. M. van der Flier,et al.  CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. , 2009, JAMA.

[7]  K. Blennow,et al.  Cerebrospinal fluid α-synuclein in neurodegenerative disorders—A marker of synapse loss? , 2009, Neuroscience Letters.

[8]  S. Lorenzl,et al.  Increased α-synuclein aggregation following limited cleavage by certain matrix metalloproteinases , 2009, Experimental Neurology.

[9]  J. Winderickx,et al.  Phosphorylation, lipid raft interaction and traffic of alpha-synuclein in a yeast model for Parkinson. , 2008, Biochimica et biophysica acta.

[10]  B. Mollenhauer,et al.  Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration , 2008, Experimental Neurology.

[11]  L. Lopiano,et al.  α-synuclein and Parkinson’s disease: a proteomic view , 2008, Expert review of proteomics.

[12]  A. C. Belin,et al.  Parkinson’s disease: A genetic perspective , 2008, The FEBS journal.

[13]  G. Halliday,et al.  Human-based studies on α-synuclein deposition and relationship to Parkinson's disease symptoms , 2008, Experimental Neurology.

[14]  G. Halliday,et al.  Human-based studies on alpha-synuclein deposition and relationship to Parkinson's disease symptoms. , 2008, Experimental neurology.

[15]  I. Ferrer,et al.  Identification and characterization of a new alpha-synuclein isoform and its role in Lewy body diseases , 2008, Neurogenetics.

[16]  Henrik Zetterberg,et al.  Characterization of amyloid beta peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. , 2007, Journal of proteome research.

[17]  N. Kelleher,et al.  Decoding protein modifications using top-down mass spectrometry , 2007, Nature Methods.

[18]  R. Nelson,et al.  Investigation of Human Protein Variants and Their Frequency in the General Population*S , 2007, Molecular & Cellular Proteomics.

[19]  K. Blennow,et al.  Aspects of beta-amyloid as a biomarker for Alzheimer's disease. , 2007, Biomarkers in medicine.

[20]  E. Perry,et al.  Differences in neuropathologic characteristics across the Lewy body dementia spectrum , 2006, Neurology.

[21]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[22]  M. Onofrj,et al.  Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.

[23]  A. Delacourte,et al.  Biochemical Staging of Synucleinopathy and Amyloid Deposition in Dementia With Lewy Bodies , 2006, Journal of neuropathology and experimental neurology.

[24]  J. Growdon,et al.  Clinical and biochemical correlates of insoluble alpha-synuclein in dementia with Lewy bodies. , 2006, Acta neuropathologica.

[25]  J. Growdon,et al.  Clinical and biochemical correlates of insoluble α-synuclein in dementia with Lewy bodies , 2006, Acta Neuropathologica.

[26]  N. Hattori,et al.  A Combinatorial Code for the Interaction of α-Synuclein with Membranes* , 2005, Journal of Biological Chemistry.

[27]  N. Hattori,et al.  A combinatorial code for the interaction of alpha-synuclein with membranes. , 2005, The Journal of biological chemistry.

[28]  D. Lynch,et al.  Functional consequences of alpha-synuclein tyrosine nitration: diminished binding to lipid vesicles and increased fibril formation. , 2004, The Journal of biological chemistry.

[29]  Hansjürgen Bratzke,et al.  Stages in the development of Parkinson’s disease-related pathology , 2004, Cell and Tissue Research.

[30]  Robert Edwards,et al.  Lipid Rafts Mediate the Synaptic Localization of α-Synuclein , 2004, The Journal of Neuroscience.

[31]  S. Deininger,et al.  "Affinity-proteomics": direct protein identification from biological material using mass spectrometric epitope mapping , 2004, Analytical and bioanalytical chemistry.

[32]  R. Edwards,et al.  Lipid rafts mediate the synaptic localization of alpha-synuclein. , 2004, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[33]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[34]  B. Ghetti,et al.  Ubiquitination of α-Synuclein in Lewy Bodies Is a Pathological Event Not Associated with Impairment of Proteasome Function* , 2003, Journal of Biological Chemistry.

[35]  P. Axelsen,et al.  Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro† , 2003 .

[36]  J. Trojanowski,et al.  Role of alpha-synuclein carboxy-terminus on fibril formation in vitro. , 2003, Biochemistry.

[37]  J. George,et al.  The synucleins , 2001, Genome Biology.

[38]  C. Masters,et al.  The solubility of α‐synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease , 2001 .

[39]  C. Masters,et al.  The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. , 2001, Journal of neurochemistry.

[40]  C. Masters,et al.  Accumulation of Insoluble α-Synuclein in Dementia with Lewy Bodies , 2000, Neurobiology of Disease.

[41]  C. Masters,et al.  Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies. , 2000, Neurobiology of disease.

[42]  B. Hyman,et al.  Clinicopathologic correlates in temporal cortex in dementia with Lewy bodies , 1999, Neurology.

[43]  J Q Trojanowski,et al.  Lewy bodies contain altered alpha-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. , 1998, The American journal of pathology.

[44]  P. Blumbergs,et al.  Multiple-system atrophy: a new α-synuclein disease? , 1998, The Lancet.

[45]  Nigel J. Cairns,et al.  Filamentous α-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies , 1998, Neuroscience Letters.

[46]  J Q Trojanowski,et al.  Aggregation of alpha-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. , 1998, The American journal of pathology.

[47]  R A Crowther,et al.  Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. , 1998, Neuroscience letters.

[48]  R. Krüger,et al.  Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. , 1998, Nature genetics.

[49]  P. Blumbergs,et al.  Multiple-system atrophy: a new alpha-synuclein disease? , 1998, Lancet.

[50]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[51]  S E Ide,et al.  Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. , 1997, Science.

[52]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.

[53]  K. Jellinger,et al.  Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. , 1996, Neurology.

[54]  R. Heilig,et al.  The NACP/synuclein gene: chromosomal assignment and screening for alterations in Alzheimer disease. , 1995, Genomics.

[55]  Michel Goedert,et al.  Identification of two distinct synucleins from human brain , 1994, FEBS letters.

[56]  E. Masliah,et al.  Molecular cloning of cDNA encoding an unrecognized component of amyloid in Alzheimer disease. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[57]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[58]  R. Bradshaw,et al.  Protein translocation and turnover in eukaryotic cells. , 1989, Trends in biochemical sciences.

[59]  R. Mohs,et al.  Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.

[60]  R. Scheller,et al.  Synuclein: a neuron-specific protein localized to the nucleus and presynaptic nerve terminal , 1988, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[61]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.